Factors associated with unsuppressed viremia in women living with HIV on lifelong ART in the multi-country US-PEPFAR PROMOTE study: A cross-sectional analysis


Autoři: Patience Atuhaire aff001;  Sherika Hanley aff002;  Nonhlanhla Yende-Zuma aff003;  Jim Aizire aff004;  Lynda Stranix-Chibanda aff005;  Bonus Makanani aff006;  Beteniko Milala aff007;  Haseena Cassim aff008;  Taha Taha aff004;  Mary Glenn Fowler aff009
Působiště autorů: Makerere University-Johns Hopkins University (MU-JHU) Kampala, Uganda aff001;  Centre for the AIDS Programme of Research in South Africa (CAPRISA), Umlazi Clinical Research Site, Nelson R. Mandela School of Medicine, Durban, South Africa aff002;  Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa aff003;  Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD, United States of America aff004;  University of Zimbabwe College of Health Sciences Department of Paediatrics and Child Health, Harare, Zimbabwe aff005;  Malawi College of Medicine-John's Hopkins Research Project, Blantyre, Malawi aff006;  University of North Carolina (UNC) Project, Lilongwe, Malawi aff007;  Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital, University of Witwatersrand, Johannesburg, South Africa aff008;  Johns Hopkins University, Departments of Pathology and Epidemiology, Baltimore, MD, United States of America aff009
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0219415

Souhrn

Background

Despite recent efforts to scale-up lifelong combination antiretroviral therapy (cART) in sub-Saharan Africa, high rates of unsuppressed viremia persist among cART users, and many countries in the region fall short of the UNAIDS 2020 target to have 90% virally suppressed. We sought to determine the factors associated with unsuppressed viremia (defined for the purpose of this study as >200 copies/ml) among sub-Saharan African women on lifelong cART.

Methods

This cross-sectional analysis was based on baseline data of the PROMOTE longitudinal cohort study at 8 sites in Uganda, Malawi, Zimbabwe and South Africa. The study enrolled 1987 women living with HIV who initiated lifelong cART at least 1–5 years ago. Socio-demographic, clinical, and cART adherence data were collected. We used multivariable Poisson regression with robust variance to identify factors associated with unsuppressed viremia.

Results

At enrolment, 1947/1987 (98%) women reported taking cART. Of these, HIV-1 remained detectable in 293/1934 (15%), while 216/1934 (11.2%) were considered unsuppressed (>200 copies/ml). The following factors were associated with an increased risk of unsuppressed viremia: not having household electricity (adjusted prevalence risk ratio (aPRR) 1.74, 95% confidence interval (CI) 1.28–2.36, p<0.001); not being married (aPRR 1.32, 95% CI 0.99–1.78, p = 0.061), self-reported missed cART doses (aPRR 1.63, 95% CI 1.24–2.13, p<0.001); recent hospitalization (aPRR 2.48, 95% CI 1.28–4.80, p = 0.007) and experiencing abnormal vaginal discharge in the last three months (aPRR 1.88; 95% CI 1.16–3.04, p = 0.010). Longer time on cART (aPRR 0.75, 95% CI 0.64–0.88, p<0.001) and being older (aPRR 0.77, 95% CI 0.76–0.88, p<0.001) were associated with reduced risk of unsuppressed viremia.

Conclusion

Socioeconomic barriers such as poverty, and individual barriers like not being married, young age, and self-reported missed doses are key predictors of unsuppressed viremia. Targeted interventions are needed to improve cART adherence among women living with HIV with this risk factor profile.

Klíčová slova:

Antiretroviral therapy – Dose prediction methods – HIV – Malawi – Uganda – Viral load – Viremia – Zimbabwe


Zdroje

1. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach: World Health Organization; 2016.

2. UNAIDS. Global HIV & AIDS Statistics Update 2019. UNAIDS: Joint United Nations Programme on HIV/AIDS (UNAIDS) 2019.

3. UNAIDS. Global HIV/AIDS statistics facts sheet: UNAIDS; 2018 [July 2018].

4. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-, middle and high income countries: a systematic review and meta-analysis. AIDS (London, England). 2012;26(16):2039.

5. Haberer JE, Sabin L, Amico KR, Orrell C, Galárraga O, Tsai AC, et al. Improving antiretroviral therapy adherence in resource‐limited settings at scale: a discussion of interventions and recommendations. Journal of the International AIDS Society. 2017;20(1):21371. doi: 10.7448/IAS.20.1.21371 28630651

6. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014–July 2015. BMC infectious diseases. 2017;17(1):326. doi: 10.1186/s12879-017-2428-3 28468608

7. Corless IB, Hoyt AJ, Tyer-Viola L, Sefcik E, Kemppainen J, Holzemer WL, et al. 90-90-90-Plus: Maintaining Adherence to Antiretroviral Therapies. AIDS Patient Care and STDs. 2017;31(5):227–36. doi: 10.1089/apc.2017.0009 28514193

8. Henegar CE, Westreich DJ, Maskew M, Miller WC, Brookhart MA, Van Rie A. The effect of pregnancy and the postpartum period on adherence to antiretroviral therapy among HIV-infected women established on treatment. Journal of acquired immune deficiency syndromes (1999). 2015;68(4):477.

9. Abuogi LL, Humphrey JM, Mpody C, Yotebieng M, Murnane PM, Clouse K, et al. Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs. Journal of virus eradication. 2018;4(Suppl 2):33–9. Epub 2018/12/06. 30515312; PubMed Central PMCID: PMC6248851.

10. Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, et al. Treatment failure, drug resistance, and CD4 T-cell count decline among postpartum women on antiretroviral therapy in South Africa. Journal of acquired immune deficiency syndromes (1999). 2016;71(1):31.

11. Katz IT, Leister E, Kacanek D, Hughes MD, Bardeguez A, Livingston E, et al. Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. Annals of internal medicine. 2015;162(2):90–9. Epub 2015/01/20. doi: 10.7326/M13-2005 25599347; PubMed Central PMCID: PMC4299931.

12. Myer L, Dunning L, Lesosky M, Hsiao NY, Phillips T, Petro G, et al. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2017;64(4):422–7. Epub 2016/12/09. doi: 10.1093/cid/ciw792 27927852; PubMed Central PMCID: PMC5849096.

13. Labhardt ND, Ringera I, Lejone TI, Cheleboi M, Wagner S, Muhairwe J, et al. When patients fail UNAIDS' last 90—the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a prospective cohort study. Journal of the International AIDS Society. 2017;20(1):21803. Epub 2017/08/05. doi: 10.7448/IAS.20.1.21803 28777506; PubMed Central PMCID: PMC5577637.

14. Hermans LE, Moorhouse M, Carmona S, Grobbee DE, Hofstra LM, Richman DD, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. The Lancet Infectious diseases. 2018;18(2):188–97. Epub 2017/11/22. doi: 10.1016/S1473-3099(17)30681-3 29158101.

15. Esber A, Polyak C, Kiweewa F, Maswai J, Owuoth J, Maganga L, et al. Persistent low level viremia predicts subsequent virologic failure. Is it time to change the 3rd 90? Clinical Infectious Diseases. 2018.

16. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. New England Journal of Medicine. 2016;375(18):1726–37. doi: 10.1056/NEJMoa1511691 27806243.

17. Taha TE, Yende-Zuma N, Aizire J, Chipato T, Wambuzi Ogwang L, Makanani B, et al. The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings. PloS one. 2018;13(12):e0208805. doi: 10.1371/journal.pone.0208805 30543692

18. Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Access date 13 Mar 2019,Page C-7.

19. EACS European AIDS Clinical Society. Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe Version 8.0 October 2015.

20. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLOS Medicine. 2016;13(11):e1002183. doi: 10.1371/journal.pmed.1002183 27898679

21. Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, et al. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda. J Acquir Immune Defic Syndr. 2017;74(3):279–84. Epub 2016/11/10. doi: 10.1097/QAI.0000000000001228 27828878; PubMed Central PMCID: PMC5303140.

22. Magadzire BP, Marchal B, Mathys T, Laing RO, Ward K. Analyzing implementation dynamics using theory-driven evaluation principles: lessons learnt from a South African centralized chronic dispensing model. BMC health services research. 2017;17(2):724.

23. Prust ML, Banda CK, Nyirenda R, Chimbwandira F, Kalua T, Jahn A, et al. Multi‐month prescriptions, fast‐track refills, and community ART groups: results from a process evaluation in Malawi on using differentiated models of care to achieve national HIV treatment goals. Journal of the International AIDS Society. 2017;20:21650. doi: 10.7448/IAS.20.5.21650 28770594

24. Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS patient care and STDs. 2015;29(3):111–6. doi: 10.1089/apc.2014.0255 25615029

25. Chawla KS, Rosenberg NE, Stanley C, Matoga M, Maluwa A, Kanyama C, et al. HIV and early hospital readmission: evaluation of a tertiary medical facility in Lilongwe, Malawi. BMC Health Serv Res. 2018;18(1):225. Epub 2018/04/03. doi: 10.1186/s12913-018-3050-9 29606125; PubMed Central PMCID: PMC5879607.

26. Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslen M, Bjorkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PloS one. 2017;12(7):e0180761. Epub 2017/07/07. doi: 10.1371/journal.pone.0180761 28683128; PubMed Central PMCID: PMC5500364.

27. Wagenlehner FM, Brockmeyer NH, Discher T, Friese K, Wichelhaus TA. The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Deutsches Arzteblatt international. 2016;113(1–02):11–22. Epub 2016/03/05. doi: 10.3238/arztebl.2016.0011 26931526; PubMed Central PMCID: PMC4746407.


Článek vyšel v časopise

PLOS One


2019 Číslo 10